|
|
Article: Merix, Kirin Collaborating For Personalized Vaccine Products.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Joined by way of a research synergy and therapeutic focus, a U.S. biotech firm is partnering with a large Japanese brewery to develop dendritic cell-based remedies.
Merix Bioscience Inc., an immunotherapy vaccine company, agreed to collaborate on therapies using dendritic cells with the pharmaceutical division of Kirin Brewery Co. Ltd., which is developing products for renal disease, cancer and immunological disorders. To that end, each party will contribute between $45 million and $65 million during the first three years of the agreement.
Clint Dederick, Merix's chairman, president and CEO, said the deal was two years in ...